Advanced Biomed Inc. Files Amendment to S-1 Registration Statement

TL;DR

<b>Advanced Biomed Inc. has filed an amendment to its S-1 registration statement, indicating a pending public offering.</b>

AI Summary

Advanced Biomed Inc. (ADVB) filed a Amended IPO Registration (S-1/A) with the SEC on January 19, 2024. Advanced Biomed Inc. filed an amendment (S-1/A) to its registration statement on January 19, 2024. The company is incorporated in Nevada and operates in the Medical Laboratories sector (SIC code 8071). Its principal executive offices are located at 689-87 Xiaodong Road, Yongkang District, Tainan, Taiwan. The filing indicates the company is a smaller reporting company and an emerging growth company. The proposed sale of securities is set to commence as soon as practicable after the effective date of the registration statement.

Why It Matters

For investors and stakeholders tracking Advanced Biomed Inc., this filing contains several important signals. This amendment signals progress towards a potential public offering, which could provide the company with capital for growth or operations. As a smaller reporting and emerging growth company, Advanced Biomed Inc. may benefit from specific regulatory accommodations, but also faces scrutiny regarding its financial health and future prospects.

Risk Assessment

Risk Level: medium — Advanced Biomed Inc. shows moderate risk based on this filing. The company is a smaller reporting company and an emerging growth company, which often implies a less established financial track record and potentially higher risk compared to larger, more mature public entities.

Analyst Insight

Monitor future filings for details on the proposed offering, including the number of shares, pricing, and use of proceeds, to assess the company's capital-raising strategy and valuation.

Key Numbers

• 2024-01-19 — Filing Date (Date the S-1/A amendment was filed)
• 333-272110 — SEC File Number (Registration statement file number)
• 8071 — SIC Code (Standard Industrial Classification Code for Medical Laboratories)

Key Players & Entities

• Advanced Biomed Inc. (company) — Registrant name
• 2024-01-19 (date) — Filing date
• 333-272110 (registration_number) — SEC registration number
• 8071 (sic_code) — Standard Industrial Classification Code
• NV (state) — State of incorporation
• Cogency Global Inc. (company) — Agent for service
• Fang Liu (person) — Attorney for registrant
• VCL Law LLP (company) — Law firm for registrant

Forward-Looking Statements

• Advanced Biomed Inc. will complete its initial public offering within the next 6-12 months. (Advanced Biomed Inc.) — medium confidence, target: 2025-01-19

FAQ

Industry Context

The company operates in the Medical Laboratories industry, which involves diagnostic testing and analysis services.

Regulatory Implications

The filing is made under the Securities Act of 1933, which governs the registration of securities offered to the public.

What Investors Should Do

1. Review the full S-1/A filing for details on the proposed securities offering, including share price and quantity.
2. Analyze the company's business description and risk factors to understand its operational strategy and potential challenges.
3. Track future SEC filings for updates on the registration statement's effectiveness and the commencement of the public offering.

Key Dates

• 2024-01-19: Filing of S-1/A Amendment — Indicates progress in the registration process for a public offering.

Year-Over-Year Comparison

This is an amendment to a previously filed registration statement, indicating ongoing efforts to go public.

Key Financial Figures

• $0.001 — 0,000 shares of common stock, par value $0.001 per share, of Advanced Biomed Inc. We e
• $4.00 — l public offering price will be between $4.00 to $5.00 per share of common stock. Pri
• $5.00 — offering price will be between $4.00 to $5.00 per share of common stock. Prior to thi

Filing Documents

• vc035_s1a.htm (S-1/A) — 2032KB
• vc035_ex15-1.htm (EX-15.1) — 4KB
• vc035_ex23-1.htm (EX-23.1) — 4KB
• vc035_img01.jpg (GRAPHIC) — 21KB
• vc035_img02.jpg (GRAPHIC) — 32KB
• vc035_img03.jpg (GRAPHIC) — 22KB
• vc035_img04.jpg (GRAPHIC) — 57KB
• vc035_img05.jpg (GRAPHIC) — 85KB
• vc035_img06.jpg (GRAPHIC) — 7KB
• vc035_img07.jpg (GRAPHIC) — 111KB
• vc035_img08.jpg (GRAPHIC) — 67KB
• vc035_img09.jpg (GRAPHIC) — 109KB
• vc035_img10.jpg (GRAPHIC) — 67KB
• vc035_img11.jpg (GRAPHIC) — 57KB
• vc035_img12.jpg (GRAPHIC) — 53KB
• vc035_img13.jpg (GRAPHIC) — 69KB
• vc035_img14.jpg (GRAPHIC) — 26KB
• vc035_img15.jpg (GRAPHIC) — 43KB
• vc035_img16.jpg (GRAPHIC) — 23KB
• vc035_img17.jpg (GRAPHIC) — 10KB
• vc035_ex15-1img01.jpg (GRAPHIC) — 26KB
• vc035_ex15-1img02.jpg (GRAPHIC) — 4KB
• vc035_ex15-1img03.jpg (GRAPHIC) — 10KB
• vc035_ex23-1img01.jpg (GRAPHIC) — 26KB
• vc035_ex23-1img02.jpg (GRAPHIC) — 4KB
• vc035_ex23-1img03.jpg (GRAPHIC) — 10KB
• 0001575872-24-000068.txt (&nbsp;) — 3335KB

From the Filing

As filed with the Securities and Exchange Commission on January 19, 2024. Registration No. 333-272110 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 AMENDMENT NO. 11 TO FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Advanced Biomed Inc. (Exact name of registrant as specified in its charter) Nevada 8071 87-2177170 (State or other jurisdiction of incorporation or organization) (Primary Standard Industrial Classification Code Number) (I.R.S. Employer Identification Number) 689-87 Xiaodong Road, Yongkang District Tainan, Taiwan Tel: 886-6-3121716 (Address, including zip code, and telephone number, including area code, of registrant&rsquo;s principal executive offices) Cogency Global Inc. 122 East 42nd Street, 18th Floor New York, NY 10168 (212) 947-7200 (Name, address, including zip code, and telephone number, including area code, of agent for service) Copies of all communications to: Fang Liu, Esq. VCL Law LLP William S. Rosenstadt, Esq. Mengyi &ldquo;Jason&rdquo; Ye, Esq. 1945 Old Gallows Road Ortoli Rosenstadt LLP Suite 260 366 Madison Avenue, 3rd Floor Vienna, VA 22182 New York, NY 10017 Telephone: (703) 919-7285 Telephone: (212) 588-0022 Approximate date of commencement of proposed sale to the public: As soon as practicable after the effective date of this registration statement. If any of the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the Securities Act of 1933, check the following box: If this Form is filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, check the following box and list the Securities Act registration If this Form is a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. If this Form is a post-effective amendment filed pursuant to Rule 462(d) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of &ldquo;large accelerated filer,&rdquo; &ldquo;accelerated filer&rdquo; and &ldquo;smaller reporting company&rdquo; in Rule 12b-2 of the Exchange Act. Large Accelerated Filer Accelerated Filer Non-Accelerated Filer Smaller Reporting Company Emerging Growth Company If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. The registrant hereby amends this registration statement on such date or dates as may be necessary to delay its effective date until the registrant shall file a further amendment which specifically states that this registration statement shall hereafter become effective in accordance with Section 8(a) of the Securities Act of 1933 or until the registration statement shall become effective on such date as the Commission, acting pursuant to said Section 8(a), may determine. The information in this preliminary prospectus is not complete and may be changed. We may not sell these securities until the registration statement filed with the SEC is effective. This preliminary prospectus is not an offer to sell nor does it seek an offer to buy these securities in any jurisdiction where the offer or sale is not permitted. dated January 19, 2024 PRELIMINARY PROSPECTUS Advanced Biomed Inc. 25,000,000 Shares of Common Stock This prospectus relates to the offer and sale of 25,000,000 shares of common stock, par value $0.001 per share, of Advanced Biomed Inc. We expect that the initial public offering price will be between $4.00 to $5.00 per share of common stock. Prior to this offering, there has been no public market for our common stock. We have applied to list our common stock on the Nasdaq Capital Market under the symbol &ldquo;ADVB.&rdquo; We believe that upon the completion of the offering contemplated by this prospectus, we will meet the standards for listing on the Nasdaq Capital Market. We cannot guarantee that we will be successful in listing our common stock on the Nasdaq Capital Market; however, we will not complete this offering unless we are so listed. Advanced Biomed Inc. (&ldquo;Advanced Biomed&rdquo;) is not an operating company but a holding company incorporated in the State of Nevada. Substantially all of the business operations are conducted in Taiwan by our Taiwan subsidiary. And we also have a subsidiary in Hong Kong

View Full Filing

View this S-1/A filing on SEC EDGAR